Pancreatic Cancer Research

ResearcherFudan UniversityNo recent work listed

Yue Fan

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-8400-4399; OpenAlex author ID A5101918963. Sources: OpenAlex.

Their work

Papers
11 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
22
Papers, trials and grants by year

2013: 2 papers · 2014: none · 2015: none · 2016: 1 paper · 2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 2 papers

Papers 11

  1. Screening of an annexin-A2-targeted heptapeptide for pancreatic adenocarcinoma localization. Co-author DOI 10.1002/1878-0261.13352↗
  2. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Co-author DOI 10.3389/fonc.2023.1109068↗
  3. Gene coexpression network approach to develop an immune prognostic model for pancreatic adenocarcinoma. Co-author DOI 10.1186/s12957-021-02201-w↗
  4. Co-treatment With Everolimus, an mTOR-Specific Antagonist, or Downregulation of ELK1 Enhances the Sensitivity of Pancreatic Cancer Cells to Genistein. Last author DOI 10.3389/fcell.2021.633035↗
  5. Comprehensive Analysis of Immunoinhibitors Identifies LGALS9 and TGFBR1 as Potential Prognostic Biomarkers for Pancreatic Cancer. Co-author DOI 10.1155/2020/6138039↗
  6. Consolidative Chemoradiotherapy After Induced Chemotherapy Is an Optimal Regimen for Locally Advanced Pancreatic Cancer. Co-author DOI 10.3389/fonc.2019.01543↗
  7. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyy063↗
  8. microRNA-454 shows anti-angiogenic and anti-metastatic activity in pancreatic ductal adenocarcinoma by targeting LRP6. Co-author PMID 28123855↗
  9. MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep22793↗
  10. Associations of GSTM1 and GSTT1 polymorphisms with pancreatic cancer risk: evidence from a meta-analysis. Co-author DOI 10.1007/s13277-012-0598-6↗
  11. HIF1 contributes to hypoxia-induced pancreatic cancer cells invasion via promoting QSOX1 expression. First author DOI 10.1159/000354460↗

Closest collaborators

The 22 strongest of 22 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Tiantao Kuang · 3 shared papers, 2017–2021 · strength 0.42
  2. Xi Guo · 3 shared papers, 2018–2023 · strength 0.33
  3. Lili Wu · 3 shared papers, 2018–2023 · strength 0.33
  4. Yuhong Zhou · 3 shared papers, 2018–2023 · strength 0.33
  5. Tianyu Li · 2 shared papers, 2020–2021 · strength 0.32
  6. Dansong Wang · 3 shared papers, 2016–2023 · strength 0.31
  7. Chenye Shi · 4 shared papers, 2013–2017 · strength 0.27
  8. Yaolin Xu · 2 shared papers, 2018–2023 · strength 0.24
  9. Wenchuan Wu · 2 shared papers, 2018–2023 · strength 0.24
  10. Xiaoqiang Gu · 1 shared paper, 2021 · strength 0.17
  11. Jianxin Qian · 1 shared paper, 2021 · strength 0.17
  12. Miao He · 1 shared paper, 2023 · strength 0.17
  13. Heyao Ma · 1 shared paper, 2023 · strength 0.17
  14. Wenhui Lou · 1 shared paper, 2023 · strength 0.17
  15. Lei Zhao · 1 shared paper, 2023 · strength 0.17
  16. Minjie Wei · 1 shared paper, 2023 · strength 0.17
  17. Wenhui Lou · 2 shared papers, 2013–2019 · strength 0.14
  18. Yuan Ji · 1 shared paper, 2019 · strength 0.09
  19. Wenhui Lou · 1 shared paper, 2018 · strength 0.07
  20. Ding-Fang Cai · 1 shared paper, 2016 · strength 0.07
  21. Wei Wei · 1 shared paper, 2016 · strength 0.07
  22. Dingfang Cai · 1 shared paper, 2013 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.